in this publication out today in Nature Communications, VAR2 Pharma co-authors describe how oncofetal chondroitin sulfate is regulated in prostate cancer. The study reports that oncofetal CS is regulated (repressed) by the androgen receptor (AR). When prostate cancer progresses into aggressive AR-independent disease states, these tumors up-regulate oncofetal CS in the tumor via an enzyme […]
